1010114-48-3

Basic information

• Product Name: 4-(5-BroMo-pyridin-2-yloxyMethyl)-piperidine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-(5-BroMo-pyridin-2-yloxyMethyl)-piperidine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-(((5-broMopyridin-2-yl)oxy)Methyl)piperidine-1-carboxylate
• CAS NO: 1010114-48-3
• Molecular Formula: C₁₆H₂₃BrN₂O₃
• Molecular Weight: 371.26942
• Mol File: 1010114-48-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 424.9±25.0 °C(Predicted)
• Appearance: /
• Density: 1.309±0.06 g/cm3(Predicted)
• PKA: 1.61±0.22(Predicted)
• CAS DataBase Reference: 4-(5-BroMo-pyridin-2-yloxyMethyl)-piperidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-BroMo-pyridin-2-yloxyMethyl)-piperidine-1-carboxylic acid tert-butyl ester(1010114-48-3)
• EPA Substance Registry System: 4-(5-BroMo-pyridin-2-yloxyMethyl)-piperidine-1-carboxylic acid tert-butyl ester(1010114-48-3)

Safety Data

• Hazardous Substances Data: 1010114-48-3(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 13466-38-1 5-bromopyridin-2-ol 
• 123855-51-6 tert-butyl 4-(hydroxymethyl)piperidin-1-carboxylate 
• 6457-49-4 4-piperidinemethanol 
• 624-28-2 2,5-dibromopyridine 

Downstream Products

• 1010111-21-3 tert-butyl 4-((5-(4-(methylsulfonyl)phenyl)pyridine-2-yloxy)methyl)piperidin-1-carboxylate 
• 1417793-67-9 5-bromo-2-(piperidin-4-ylmethoxy)pyridine hydrochloride 
• 1417793-67-9 5-bromo-2-(piperidin-4-ylmethoxy)pyridine hydrochloride 

Relevant articles and documents

CYCLOHEXENE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC DISEASE COMPRISING THE SAME AS ACTIVE INGREDIENT

The present invention relates to: a cyclohexene derivative; a preparation method thereof; and a pharmaceutical composition for preventing or treating metabolic disease comprising the same as an active ingredient. The cyclohexene derivative according to the present invention increases the intracellular activity of cyclic adenosine monophosphate (cAMP) by activating G protein-coupled receptor 119 (GPR-119) and simultaneously exhibits weight loss and hypoglycemic effects by inducing the release of glucagon-like peptide-1 (GLP-1), which is a neuroendocrine protein, and thus can be useful as a pharmaceutical composition for preventing or treating metabolic diseases such as obesity, type 1 diabetes, type 2 diabetes, inadequate glucose tolerance, insulin resistance, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia and syndrome X.

AMIDE DERIVATIVES FOR GPR119 AGONIST

The present invention relates to novel amide derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel amide derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders.

PIPERIDINE DERIVATIVES FOR G PR119 AGONIST

The present invention relates to novel piperidine derivatives, stereoisomers thereof or pharmaceutically acceptable salts thereof; methods for preparing the compound; and pharmaceutical compositions comprising the compound. The novel piperidine derivatives, according to the present invention, having an effect as GPR119 agonist can be used for treatment of metabolic disorders, including diabetes mellitus (especially type II) and related disorders